The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...

A ketogenic diet may improve symptoms of depression, according to a new review and meta-analysis published in JAMA Psychiatry ...

The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...

A diagnostic distinction for postpartum psychosis in the DSM will improve detection, treatment, and prevention, an expert ...

The FDA has approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for treating major depressive ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...

Scientists have developed a portable biosensor that can detect levels of BDNF, a protein linked to mental health conditions such as depression, schizophrenia, and bipolar disorder.

The number of South Koreans diagnosed with depression and bipolar disorder each increased nearly 1.5-fold over the past six ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The number of people in South Korea suffering from depression and bipolar disorder has increased by more than 40% over the past six years. In ...